84. サルコイドーシス Sarcoidosis Clinical trials / Disease details


臨床試験数 : 149 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02192489
(ClinicalTrials.gov)
November 1, 201415/7/2014A Phase 2 Study With CC-220 in Skin SarcoidosisA Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous SarcoidosisSarcoidosisDrug: CC-220 0.3 mg Daily;Drug: CC-220 0.6mg Daily;Drug: PlaceboCelgeneNULLWithdrawn18 YearsN/AAll0Phase 2NULL
2NCT02134717
(ClinicalTrials.gov)
January 201430/4/2014Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis ImmunophenotypesAn Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With SarcoidosisSarcoidosisDrug: all subjects will receive maraviroc 300mg orally twice a day for 6 weeks;Procedure: Bronchoscopy with bronchoalveolar lavage;Procedure: venipunctures;Procedure: Skin biopsyKevin F. GibsonUniversity of PittsburghTerminated18 Years80 YearsAll3N/AUnited States
3NCT00794274
(ClinicalTrials.gov)
November 200819/11/2008The Efficacy and Safety of CC-10004 in Chronic Cutaneous SarcoidosisThe Efficacy and Safety of CC-10004 in Chronic Cutaneous SarcoidosisSarcoidosis;Cutaneous SarcoidosisDrug: CC-100004University of CincinnatiCelgene Corporation;Medical University of South CarolinaCompleted18 Years80 YearsBoth15Phase 2/Phase 3United States